Clinical Oncology: Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

David Barry Author

barry.david@gmail.com

Subjects of specialization
Doxorubicin; Nephrotic syndrome; Pegylated liposomal doxorubicin; Thrombotic microangiopathy

Affiliation
Division of Cardiology, Department of Internal Medicine, Lankenau Medical Center, Wynnewood, Penssylvania

Biography

Dr. David Barry is working the field and division of Department of Internal Medicine, Lankenau Medical Center, Wynnewood, Pennsylvania, having specialization in IDoxorubicin; Nephrotic syndrome; Pegylated liposomal doxorubicin; Thrombotic microangiopathy

Publications

Case Report Subscription

Pegylated Liposomal Doxorubicin Induced Nephrotic Syndrome and Renal Thrombotic Microangiopathy: A Case Report and Review

Author(s):

Karl Swanson, David Barry, Talar Telvizian and Colleen O’Connor

Anthracyclines such as Pegylated Liposomal Doxorubicin (PLD) are well known for causing cardiotoxicity. Other adverse effects such as nephrotic syndrome and Drug-Induced Thrombotic Microangiopathy (DITMA) have been described in the literature but are not as well identified in clinical practice. A 76-year-old woman with metastatic breast cancer receiving PLD presented with generalized weakness and anasarca. She was found to have acute renal failure and nephrotic syndrome. After extensive workup, she was diagnosed with thrombotic microangiopathy on renal biopsy. The diagnosis of PLD-induced DITMA was made after a thorough work up ruled out other etiologies.  Literature since the 1950s shows an association between anthracyclines and nephrotoxicity, specifically the development of neph... view more»

Abstract HTML PDF

Google Scholars / Researchers Sites

Explore SciTechnol

GET THE APP